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Liver transplant (LT) is considered the best option for 
patients with hepatocellular carcinoma (HCC) confined 
into the liver and generally associated with liver cirrhosis (1). 
The Milan criteria (MC) represent a milestone in the 
selection of these patients (2). Therefore, basing on MC, 
the 5-year survival rate after LT could increase to 70%, 
with a HCC recurrence rate lower than 10% (2). Despite 
that, too many patients affected by HCC may not benefit 
from LT due to a tumor stage beyond the selection criteria. 
Over the last two decades, authors and physicians tried 
to overcome the MC exploring the opportunity to safely 
transplant patients beyond (3). Notably, the donor shortage 
and the competition between patients listed due to HCC 
and those listed for other indications, force physicians in 
selecting candidates with the best transplant benefit (3).
Nowadays, the majority of patients listed for LT receive loco-
regional treatments (LTRs) for HCC with the aim to control the 
tumor progression waiting for the LT and to improve post-LT 
outcome (4). Furthermore, LRTs allow down staging the tumor 
burden at diagnosis with the possibility to transplant patients 
unsuitable for LT at the first tumor evaluation (4).
Although the MC remains a strong predictor of post-
LT survival, many patients showed good or poor post-
LT outcome in spite attending or not those criteria. 
The strongest evidence, which has recently affirmed, 
demonstrates that the biological tumor behaviour may 
impair results even in patients with safe morphological 
criteria (tumor size and number). By this way, the relevance 
of the alpha-fetoprotein and tumor response to the LRTs 
has significantly grown up. Indeed, the most recent staging 
systems include the consideration of tumor biology’s clues 
such as the progression after LRTs or the absolute value and 
trend of the alpha-fetoprotein before transplant (5-7).
Accordingly, the Metroticket 2.0 is one of the most 
accurate models able to predict post-LT HCC related 
survival basing on tumor number and size and alpha-
fetoprotein evaluated at the last re-staging time (5).
On 2016, Mazzaferro et al. (8) proposed a philosophical 
framework about the transplantable tumor (TT) including 
all the pre-operative variables related to the tumor stage, 
opportunity of downstaging, and response to the LRTs 
before the transplant. TTs were classified into 8 stages 
with progression from lower stage with fewer priorities to 
the transplant until the highest stage with highest priority. 
A recent study tried to validate the prediction power of 
this staging system on a real patient cohort, exploring the 
correlation between the stages and the dropout risk before 
LT and the correlation between tumor stages and risk of 
post-LT HCC related death (9). Therefore, the TT staging 
appeared predictive for both higher and lower risk classes. 
However, it resulted inaccurate for the intermediate classes. 
Indeed, patients classified at intermediate risk appeared 
Editorial
Hepatocellular carcinoma and liver transplant: beyond the Milan 
criteria and the risk of “short-blanket” syndrome
Stefano Gitto1#, Stefano Di Sandro2#, Paolo Magistri2, Pietro Andreone3, Fabrizio Di Benedetto2
1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 2Hepato-Pancreato-Biliary Surgery and Liver 
Transplantation Unit, 3Internal and Metabolic Medicine, AOU di Modena and University of Modena and Reggio Emilia, Modena, Italy
#These authors contributed equally to this work.
Correspondence to: Pietro Andreone. Internal and Metabolic Medicine, AOU di Modena and University of Modena and Reggio Emilia, Modena 
41126, Italy. Email: pietro.andreone@unimore.it.
Provenance and Peer Review: This article was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition. The article did not undergo 
external peer review.
Comment on: Mehta N, Dodge JL, Grab JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence 
of tumor burden, alpha-fetoprotein, and wait time. Hepatology. 2020;71:943-54.
Submitted Nov 06, 2019. Accepted for publication Nov 21, 2019.
doi: 10.21037/hbsn.2019.11.34
View this article at: http://dx.doi.org/10.21037/hbsn.2019.11.34
521
HepatoBiliary Surgery and Nutrition, Vol 9, No 4 August 2020 519
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2020;9(4):518-521 | http://dx.doi.org/10.21037/hbsn.2019.11.34
having benefit from a delayed transplant (longer than 
2 months since the last tumor staging) (9). The message to 
delay a LT in view to improve the post-LT patient survival 
should be taken with caution. Although selected patients may 
benefit of a postponed transplant, in term of overall survival 
and specific tumor survival compared to an earlier transplant, 
the risk of patient drop-out waiting for a delayed transplant 
may be the really worst scenario for the patient himself.
Mehta et al. (10) recently approached this complex issue 
with a well-designed national study. Authors retrospectively 
analysed data from United Network for Organ Sharing 
(UNOS) database about LT for HCC between 2012 
and 2015. Candidates were classified into the following 
subgroups: (I) “Milan criteria” group (patients with HCC 
continuously within homonym criteria); (II) “UNOS-DS” 
group (UNOS down-staging inclusion criteria: 1 lesion >5 
and ≤8 cm, 2–3 lesions at least one >3 and ≤5 cm with total 
tumor diameter ≤8 cm, or 4–5 lesions each ≤3 cm with total 
tumor diameter ≤8 cm); (III) “AC-DS” group (initial tumor 
burden exceeding UNOS-DS inclusion criteria with no 
upper burden limit).
Notably, the subgroups 2 included patients selected 
according to UNOS-DS criteria adopted by 2017. The same 
authors already tested these standards in a multi-centre study 
with brilliant 5-year post-LT survival (80%) (11).
Authors subdivided the UNOS regions according to the 
median time from listing to LT [>9 months waitlist times 
was long wait region (LWR), 3–9 months mid wait region 
(MWR), and <3 months was considered short wait region 
(SWR), respectively] and registered the alpha-fetoprotein 
(AFP) at the time of LT.
Authors analysed data from 3,819 patients (85.8% were 
in the first subgroup, 11.0% in the second, 3.2% in the third 
one). The 3-year cumulative post-LT survival was 83.2% in 
the Milan group, 79.1% in the UNOS-DS group (P=0.17 vs. 
Milan), and 71.4% in the AC-DS group (P=0.04 vs. Milan). 
Indeed, the Milan and UNOS-DS groups showed the same 
3-year survival. However, only in the second and third 
subgroups, substantial differences in post-LT survival were 
detected according to the waiting time region. In UNOS-DS 
group, the 3-year post-LT survival was lower in MWR (72.5%) 
and SWR (78.7%) compared to LWR (92.3%) (P=0.009) with 
the same (but not statistically significant) trends for AC-DS 
group (LWR: 93.3%, MWR: 65.7%, SWR: 73.0%).
Post-LT HCC recurrence was observed in 4.4% of 
patients of Milan groups vs. 9.2% and 10.7% of the others 
two (P<0.001).
Then, authors conducted univariate and multivariate 
analysis for searching predictors of post-LT survival 
and HCC recurrence. Notably, authors considered only 
subgroups at major risk of worse outcome (subgroups 2 and 
3). Authors demonstrated that short or mid permanence on 
waitlist (with consequent short or mid cancer observation 
before LT) together with AFP >100 ng/mL, strongly 
correlate with worse post-LT survival. Furthermore, they 
reported that AFP >100 ng/mL was the only independent 
predictor of post-LT HCC recurrence.
Data from this study clearly indicate the significance 
of acquiring a minimal observation time to establish the 
effectiveness of down-staging (DS) approach. At the same 
time, AFP level seems to have a chief role in stratifying the 
risk of HCC recurrence. In this regard, authors used this 
study to validate the risk estimation of tumor recurrence 
after transplant (RETREAT) score, suitable for predicting 
post-LT HCC recurrence in the DS populations. Increasing 
RETREAT scores not only predicted increased post-
LT HCC recurrence but worse post-LT survival too. 
Remarkably, RETREAT score computes AFP at LT, 
microvascular invasion, and the sum of the largest viable 
tumor plus number of viable tumors on explant (12).
Although the study demonstrates important results 
concerning the correlation between HCC DS and results 
after LT, some limitations oblige to carefully consider the 
final messages. First, the correlation between the pre-
transplant HCC management and post-LT results should be 
designed by an intention-to-treat point of view, basing on the 
necessity to balance the risk of patient drop-out before the 
transplant and the post-LT survival or HCC specific survival. 
The effect of the time-to-transplant, fast or slow between 
listing and transplant, and the patient survival should take 
into account how many patients have lost the chance to be 
transplanted because of tumor progression. The different 
survival reported by Mehta and co-workers among SWR, 
MWR, and LWR may be re-balanced after an intention-
to-treat analysis and this is mandatory. Secondly, although 
the large collected series and the accurate study methods, 
the median follow-up of 1.9 years appears significantly 
short to draw grounded conclusions with risk of HCC 
recurrence’s underestimation. Moreover, the RETREAT 
score has strongly demonstrated its validity as predictive tool 
of HCC recurrence after transplant. However, the scientific 
community has recently concentrated its attention on the 
pre-transplant variables, with the aim to obtain information 
as much as possible before LT, rather than after. Indeed, 
despite the accurate radiological restaging since all the group 
2 and 3 patients resulted attending the transplant criteria, 
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32.5% and 40.5% of patients were outside the criteria at the 
explant tumor staging. By the Mehta’s study (10) we could 
not understand the interval between the last re-staging and 
the transplant, thus it results difficult distinguishing between 
a radiological tumor underestimation or tumor progression 
in the time between last re-staging and transplant.
The reproducibility of the study results appears 
difficult since the stratification of wait time is not based on 
individual variables but on the UNOS regions.
Other open question regards the possible use of AFP for 
the selection of candidates. This study (10), but also others 
(5,7), underlined the relevance of AFP for improving the 
selection criteria in terms of HCC recurrence prediction. 
However, we well know that 30–40% of HCC are diagnosed 
with normal serum AFP (13) and this might represent a 
potential limitation for the clinical application.
Furthermore, other tools for a better selection of LT 
candidates should be evaluated such as alternative serum 
markers [e.g., lens culinaris-agglutinin-reactive fraction of 
AFP (AFP-L3) and protein induced by vitamin K absence 
or antagonist-II (PIVKA-II)] (14) and/or hepatic gene 
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